鼻内递送羊膜细胞分泌组介导视神经创伤后RGC神经保护
该研究在小鼠视神经夹伤模型中,每日鼻内给予ST266(羊膜来源多能祖细胞的生物蛋白分泌组)或PBS,评估视网膜神经节细胞(RGC)功能、存活及视神经轴突和髓鞘损伤。结果显示,1秒夹伤后ST266显著减轻OKR下降、减少轴突和髓鞘损伤并阻止RGC丢失;4秒夹伤后ST266增加RGC存活并呈减少轴突和髓鞘损伤趋势。结论认为ST266显著减轻创伤性视神经病变,鼻内递送可能成为眼和视神经的无创治疗方式。
要点
- 1秒视神经夹伤后每日鼻内ST266 5天,显著减轻OKR下降并阻止RGC丢失。
- 4秒夹伤后鼻内ST266增加RGC存活,并呈减少RGC轴突和髓鞘损伤趋势。
核心结论
- ST266显著减轻创伤性视神经病变。
- ST266在视神经炎和创伤性视神经病变中的神经保护作用提示其可能广泛用于预防多种视神经疾病的神经元损伤。
- 结果支持鼻内递送作为眼和视神经的一种新型无创治疗方式。
研究设计与样本
- 在C57BL/6J小鼠中手术诱导视神经夹伤。
- 小鼠每日接受鼻内PBS或ST266治疗。
- 通过视动反应(OKR)评估RGC功能,计数RGC,并用luxol fast blue和抗神经丝抗体染色视神经切片以评估髓鞘和RGC轴突损伤。
主要发现
- 从1秒视神经夹伤时开始每日鼻内ST266 5天,显著减轻OKR下降。
- ST266治疗减少视神经内RGC轴突和髓鞘损伤,并阻止RGC丢失。
- 4秒视神经夹伤后,鼻内ST266增加RGC存活,并呈减少RGC轴突和髓鞘损伤趋势。
关键数值与推荐
- 鼻内ST266每日给药,从1秒视神经夹伤时开始持续5天。
- 4秒视神经夹伤后鼻内ST266增加RGC存活。
临床怎么用
- 鼻内递送ST266可能作为创伤性视神经病变及其他视神经病变的无创治疗方式。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Intranasally delivered ST266, the biological, proteinaceous secretome of amnion-derived multipotent progenitor cells, reduces retinal ganglion cell (RGC) loss, optic nerve inflammation, and demyelination in experimental optic neuritis. This unique therapy and novel administration route delivers numerous cytokines and growth factors to the eye and optic nerve, suggesting a potential to also treat other optic neuropathies. Thus, ST266-mediated neuroprotection was examined following traumatic optic nerve injury. METHODS: Optic nerve crush injury was surgically induced in C57BL/6J mice. Mice were treated daily with intranasal PBS or ST266. RGC function was assessed by optokinetic responses (OKRs), RGCs were counted, and optic nerve sections were stained with luxol fast blue and anti-neurofilament antibodies to assess myelin and RGC axon damage. RESULTS: Intranasal ST266 administered daily for 5 days, beginning at the time that a 1-second optic nerve crush was performed, significantly attenuated OKR decreases. Furthermore, ST266 treatment reduced damage to RGC axons and myelin within optic nerves, and blocked RGC loss. Following a 4-second optic nerve crush, intranasal ST266 increased RGC survival and showed a trend toward reduced RGC axon and myelin damage. Ten days following optic nerve crush, ST266 prevented myelin damage, while also inducing a trend toward increased RGC survival and visual function. CONCLUSIONS: ST266 significantly attenuates traumatic optic neuropathy. Neuroprotective effects of this unique combination of biologic molecules observed here and previously in optic neuritis suggest potential broad application for preventing neuronal damage in multiple optic nerve disorders. Furthermore, results support intranasal delivery as a novel, noninvasive therapeutic modality for eyes and optic nerves.
引用
- Grinblat GA, Khan RS, Dine K, et al. RGC Neuroprotection Following Optic Nerve Trauma Mediated By Intranasal Delivery of Amnion Cell Secretome. Invest Ophthalmol Vis Sci. 2018. PMID: 29847652. doi:10.1167/iovs.18-24096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。